Diagnostic and therapeutic practices of cardiac sarcoidosis in the United States: a nationwide questionnaire based study
Main Article Content
Keywords
cardiac sarcoidosis, registry, infiltrative cardiomyopathy, non-ischemic heart disease
Abstract
Background and aim: Cardiac sarcoidosis (CS) is the second most common cause of death in patients with sarcoidosis and data pertaining to its diagnosis and management is limited. We sought to describe diagnostic modalities and management of patients with CS in the United States, based on a national registry questionnaire. Methods: We conducted a retrospective study based on a national registry investigating 3,835 respondents to the Foundation for Sarcoidosis Research Questionnaire. The registry includes patient surveys completed between June 2014 and August 2019. Summary and univariate analyses were performed. Results: A total of 394 patients (10.3%) with CS were identified; 57% (n=223) were women and 81% (n=317) were white. The mean (±SD) age at diagnosis was 45 years (±13). CS was the initial presentation of sarcoidosis in 30%. Multiorgan involvement (≥3 organs) was present in 68%. Two-thirds of patients were admitted at least once to the hospital. Cardiac magnetic resonance imaging (74.4%) was the most common diagnostic modality used followed by positron emission tomography (PET) scan (59.3%) and cardiac biopsy (n=52, 13%). Most patients received corticosteroids (86%) and steroid-sparing medications (61%) including methotrexate (26%) and tumor necrosis factor (TNF) inhibitors (19%). A combined cardioverter defibrillator and pacemaker (39%) was the most common cardiac device implanted. Conclusions: The prevalence of CS in this cohort was higher than previously described. CS was a common initial presentation of sarcoidosis. The diagnosis was most likely made using cMRI. Steroids, methotrexate and infliximab are the most common medications used. Conduction abnormalities and arrhythmias often occurred.
References
2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736-755. doi: 10.1164/ajrccm.160.2.ats4-99.
3. Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac Sarcoidosis. Clin Chest Med. 2015;36:657-668. doi: 10.1016/j.ccm.2015.08.008.
4. Yoon HY, Kim HM, Kim YJ, Song JW. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. 2018;19:158. doi: 10.1186/s12931-018-0871-3.
5. Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48:1690-1699. doi: 10.1183/13993003.00477-2016
6. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58:1204-1211. doi: 10.1161/01.cir.58.6.1204.
7. Wicks EC, Menezes LJ, Elliott PM. Improving the diagnostic accuracy for detecting cardiac sarcoidosis. Expert Rev Cardiovasc Ther. 2015;13:223-236. doi: 10.1586/14779072.2015.1001367
8. Trivieri MG, Spagnolo P, Birnie D, et al. Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76:1878-1901. doi: 10.1016/j.jacc.2020.08.042.
9. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303-309. doi: 10.1161/CIRCEP.110.959254.
10. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25:875-881. doi: 10.1111/jce.12401
11. Tung R, Bauer B, Schelbert H, et al. Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis. Heart Rhythm. 2015;12:2488-2498. doi: 10.1016/j.hrthm.2015.08.014
12. Nery PB, Mc Ardle BA, Redpath CJ, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014;37:364-374. doi: 10.1111/pace.12277
13. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131:624-632. doi: 10.1161/CIRCULATIONAHA.114.011522
14. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977;63:86-108. doi: 10.1016/0002-9343(77)90121-8.
15. Philips B, Madhavan S, James CA, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014;7:230-236. doi: 10.1161/CIRCEP.113.000932
16. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138:299-302. doi: 10.1016/s0002-8703(99)70115-8.
17. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis. Circ J. 2019;83:2329-2388. doi: 10.1253/circj.CJ-19-0508
18. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014 Jul;11(7):1305-23. doi: 10.1016/j.hrthm.2014.03.043. Epub 2014 May 9. PMID: 24819193.
19. Darlington P, Gabrielsen A, Cederlund K, et al. Diagnostic approach for cardiac involvement in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):11-17. doi: 10.36141/svdld.v36i1.7132.
20. Smedema J-P, van Geus R-J, Truter R, Mayosi BM, Crijns HJ. Contrast-Enhanced Cardiac Magnetic Resonance: Distinction between cardiac sarcoidosis and infarction scar. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):307-314. doi: 10.36141/svdld.v34i4.5715.
21. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-248. doi: 10.2967/jnumed.111.090662
22. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10:411-420. doi: 10.1016/j.jcmg.2016.05.009
23. Padala SK, Peaslee S, Sidhu MS, Steckman DA, Judson MA. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol. 2017;227:565-570. doi: 10.1016/j.ijcard.2016.10.101
24. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034-1041. doi: 10.1016/j.cjca.2013.02.004
25. Grabowska O, Martusewicz-Boros MM, Piotrowska-Kownacka D, Wiatr E. A case report of steroid resistant cardiac sarcoidosis successfully managed with methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):178-181. doi: 10.36141/svdld.v35i2.6554.
26. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:119-127.
27. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-1889. doi: 10.1164/ajrccm.164.10.2104046.
28. Innabi A, Alzghoul BN, Kalra S, et al. Sarcoidosis among US Hispanics in a Nationwide Registry. Respir Med. 2021;190:106682. doi: 10.1016/j.rmed.2021.106682
29. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164:2085-2091. doi: 10.1164/ajrccm.164.11.2106001.
30. Cain MA, Metzl MD, Patel AR, et al. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014;113:1556-1560. doi: 10.1016/j.amjcard.2014.01.434
31. Yafasova A, Fosbøl EL, Schou M, et al. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. J Am Coll Cardiol. 2020;76:767-777. doi: 10.1016/j.jacc.2020.06.038.
32. Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging. 2018;11:e007030. doi: 10.1161/CIRCIMAGING.117.007030.
33. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010. doi: 10.1016/s0002-9149(01)01978-6.
34. Ballul T, Borie R, Crestani B, et al. Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol. 2019;276:208-211. doi: 10.1016/j.ijcard.2018.11.131
35. Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014;53:427-433. doi: 10.2169/internalmedicine.53.0794
36. Hamzeh N, Voelker A, Forssén A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108:1663-1669.doi: 10.1016/j.rmed.2014.09.013
37. Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med. 2003;253:18-30. doi: 10.1046/j.1365-2796.2003.01074.x.
38. Harper LJ, McCarthy M, Ribeiro Neto ML, et al. Infliximab for Refractory Cardiac Sarcoidosis. Am J Cardiol. 2019;124:1630-1635. doi: 10.1016/j.amjcard.2019.07.067
39. Bakker ALM, Mathijssen H, Azzahhafi J, et al. Effectiveness and safety of infliximab in cardiac Sarcoidosis. Int J Cardiol. 2021;330:179-185.doi: 10.1016/j.ijcard.2021.02.022.
40. Baker MC, Sheth K, Witteles R, Genovese MC, Shoor S, Simard JF. TNF-alpha inhibition for the treatment of cardiac sarcoidosis [published correction appears in Semin Arthritis Rheum. 2021 Dec;51(6):1390]. Semin Arthritis Rheum. 2020;50(3):546-552.
41. Rosenthal DG, Parwani P, Murray TO, et al. Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis. J Am Heart Assoc. 2019;8:e010952. doi: 10.1161/JAHA.118.010952
42. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009;6:189-195.doi: 10.1016/j.hrthm.2008.10.039.
43. Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505-509.doi: 10.1016/j.amjcard.2014.11.028.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
